title: Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
authors.affiliation: Department of Dermatology, Archet Hospital-Centre Hospitalier Universitaire de Nice, Nice cedex 03, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Bahadoran
authors.forename: Maryline
authors.initials: M
authors.lastname: Allegra
authors.forename: Florence
authors.initials: F
authors.lastname: Le Duff
authors.forename: Elodie
authors.initials: E
authors.lastname: Long-Mira
authors.forename: Paul
authors.initials: P
authors.lastname: Hofman
authors.forename: Damien
authors.initials: D
authors.lastname: Giacchero
authors.forename: Thierry
authors.initials: T
authors.lastname: Passeron
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Lacour
authors.forename: Robert
authors.initials: R
authors.lastname: Ballotti
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001120:Arginine; D001415:Back; D002470:Cell Survival / Q000187:drug effects; D004789:Enzyme Activation; D048049:Extracellular Signal-Regulated MAP Kinases / Q000187:drug effects; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology; D007930:Leucine; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D010091:Oximes / Q000008:administration & dosage / Q000494:pharmacology; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000494:pharmacology; D017354:Point Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics; D000077157:Sorafenib; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D007211:Indoles; D010091:Oximes; D010671:Phenylurea Compounds; D013449:Sulfonamides; D000077484:Vemurafenib; D009536:Niacinamide; D001120:Arginine; D000077157:Sorafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D048049:Extracellular Signal-Regulated MAP Kinases; D007930:Leucine; C561627:dabrafenib